International Scholarly Research Notices

Clinical Study

Symptom Distress Associated with Biopsy in Women with Suspect Breast Lesions

Table 1

Descriptive statistics for outcome measures for ALL participants and by diagnostic status^* at pre- () and post-biopsy () visits.


Outcome measure	Visit	All participants	BC positive participants	BC negative participants
Outcome measure	Visit	Mean SD	Mean SD	Mean SD

Anxiety subscale of HADS		8.53 3.63 (n = 38)	9.00 2.37 (n = 11)	8.33 4.06 (n = 27)
Anxiety subscale of HADS		7.61 3.49 (n = 38)	8.46 2.88 (n = 11)	7.26 3.71 (n = 27)
Depressive subscale of HADS		4.66 3.57 (n = 38)	3.91 3.08 (n = 11)	4.96 3.77 (n = 27)
Depressive subscale of HADS		4.08 4.05 (n = 38)	3.45 3.59 (n = 11)	4.33 4.26 (n = 27)
Fatigue (BFI)		2.78 2.17 (n = 47)	2.79 1.34 (n = 15)	2.77 2.49 (n = 32)
Fatigue (BFI)		2.68 1.99 (n = 47)	2.62 1.34 (n = 15)	2.70 2.25 (n = 32)
Fatigue level (BFI)		1.28 0.50 (n = 47)	1.20 0.41 (n = 15)	1.31 0.54 (n = 32)
Fatigue level (BFI)		1.26 0.49 (n = 47)	1.13 0.35 (n = 15)	1.31 0.54 (n = 32)
Sleep (PSQI)		7.13 3.59 (n = 47)	6.60 2.64 (n = 15)	7.38 3.97 (n = 32)
Sleep (PSQI)		7.15 3.72 (n = 46)	6.86 3.94 (n = 14)	7.28 3.67 (n = 32)
PANAS positive subscale		33.17 9.58 (n = 47)	33.60 6.48 (n = 15)	32.97 10.83 (n = 32)
PANAS positive subscale		33.39 9.30 (n = 46)	31.57 7.17 (n = 14)	34.19 10.09 (n = 32)
PANAS negative subscale		21.72 7.75 (n = 47)	21.73 7.75 (n = 15)	21.72 7.88 (n = 32)
PANAS negative subscale		20.83 7.84 (n = 46)	23.21 8.41 (n = 14)	19.78 7.48 (n = 32)
Quality of life (EORTC)		74.82 18.91 (n = 47)	77.78 12.86 (n = 15)	73.44 21.21 (n = 32)
Quality of life (EORTC)		71.28 21.69 (n = 47)	69.44 15.00 (n = 15)	72.14 24.37 (n = 32)
Modified social support (MSSS)		76.56 22.63 (n = 46)	79.58 17.63 (n = 14)	75.24 24.64 (n = 32)
Modified social support (MSSS)		77.52 26.81 (n = 47)	89.57 16.77 (n = 15)	71.88 28.92 (n = 32)
C-reactive protein (CRP)^**		7248.06 7823.91 (n = 47)	6601.80 8583.84 (n = 15)	7551.00 7567.07 (n = 32)
C-reactive protein (CRP)^**		8358.26 8597.71 (n = 47)	9696.07 11426.52 (n = 15)	7731.16 7032.20 (n=32)
Interleukin-6 (IL-6)^**		348.59 616.14 (n = 34)	273.84 472.48 (n = 11)	384.34 681.06 (n = 23)
Interleukin-6 (IL-6)^**		296.29 556.48 (n = 39)	213.49 443.79 (n = 14)	342.66 614.32 (n = 25)

BC: breast cancer, ^*Diagnostic status (BC+ or BC−) was determined after biopsy. It is important to note that participants are not aware of their BC status at the first () visit, ^**Marker on inflammation.